Patients with T-cell acute lymphoblastic leukaemia (T-ALL) and the closely related peripheral T-cell lymphoblastic lymphoma ...
T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to ...
Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients ...
LB2501: Promising Phase 1 Trial of In Vivo CAR-T Data Demonstrate High Response Rates in B-cell Malignancies ...
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric ...
Legend Biotech (LGND) stock jumps as the company posts early-stage trial data for in vivo CAR-T cell therapy in B-cell ...
Researchers at University of Tsukuba have identified multiple T-cell subtypes with unique characteristics in follicular lymphoma, a prevalent type of blood cancer. These T cells regulate the ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
St. David's South Austin enrolled the first patient in a global lymphoma therapy study using a next-generation CAR T approach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results